PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells

Journal of Immunology

Volumn 182, Issue 5, 2009, Pages 2816-2826

  Parekh, Vrajesh V ^a   Lalani, Saif ^a   Kim, Sungjune ^a   Halder, Ramesh ^b   Azuma, Miyuki ^c   Yagita, Hideo ^d   Kumar, Vipin ^b   Wu, Lan ^a   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CELL PROTEIN PROGRAMMED DEATH 1; CELL PROTEIN PROGRAMMED DEATH LIGAND 1; CELL PROTEIN PROGRAMMED DEATH LIGAND 2; GLYCOLIPID; GLYCOSPHINGOLIPID ALPHA GALACTOSYLCERAMIDE; SULFATIDE; UNCLASSIFIED DRUG; ALPHA GALACTOSYLCERAMIDE; ALPHA-GALACTOSYLCERAMIDE; APOPTOSIS REGULATORY PROTEIN; B7 ANTIGEN; GALACTOSYLCERAMIDE; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PDCD1 PROTEIN, MOUSE; PDCD1LG1 PROTEIN, MOUSE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; FEMALE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; UPREGULATION; ANIMAL; C57BL MOUSE; CYTOLOGY; CYTOTOXICITY; DRUG ANTAGONISM; EXPERIMENTAL MELANOMA; GENETIC VARIABILITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE MUTANT; NATURAL KILLER T CELL; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CLONAL ANERGY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GALACTOSYLCERAMIDES; GENETIC VARIATION; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; PEPTIDES; SIGNAL TRANSDUCTION;

EID: 64849116017     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803648     Document Type: Article

References (59)

1. Taniguchi, M., M. Harada, S. Kojo, T. Nakayama, and H. Wakao. 2003. The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21: 483-513.
2. Brigl, M., and M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890.
3. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 26: 877-900.
4. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
5. Borg, N. A., K. S. Wun, L. Kjer-Nielsen, M. C. Wilce, D. G. Pellicci, R. Koh, G. S. Besra, M. Bharadwaj, D. I. Godfrey, J. McCluskey, and J. Rossjohn. 2007. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448: 44-49.
6. Godfrey, D. I., H. R. MacDonald, M. Kronenberg, M. J. Smyth, and L. Van Kaer. 2004. NKT cells: what's in a name? Nat. Rev. Immunol. 4: 231-237.
7. Mattner, J., K. L. DeBord, N. Ismail, R. D. Goff, C. I. Cantu, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529.
8. Kinjo, Y., D. Y. Wu, G. Kim, G.-W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C.-H. Wong, and M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525.
9. Sriram, V., W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2005. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligand for NKT cells. Eur. J. Immunol. 35: 1692-1701.
10. Kinjo, Y., E. Tupin, D. Wu, M. Fujio, R. Garcia-Navarro, M. Benhnia, D. M. Zajonc, G. Ben-Menachem, G. D. Ainge, G. F. Painter, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7: 978-986.
11. Zhou, D., J. Mattner, C. Cantu, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. Wu, T. Yamashita, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
12. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki, and M. Taniguchi. 1997. CD1drestricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 278: 1626-1629.
13. Parekh, V. V., M. T. Wilson, and L. Van Kaer. 2005. iNKT-cell responses to glycolipids. Crit. Rev. Immunol. 25: 183-213.
14. Kim, S., S. Lalani, V. V. Parekh, L. Wu, and L. Van Kaer. 2008. Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev. Vaccines 7: 1519-1532.
15. Seino, K., S. Motohashi, T. Fujisawa, T. Nakayama, and M. Taniguchi. 2006. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 97: 807-812.
16. Fujii, S. 2008. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol. 29: 242-249.
17. Van Kaer, L. 2005. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5: 31-42.
18. Wilson, M. T., C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C. R. Wang, S. Joyce, M. J. Wick, and L. Van Kaer. 2003. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA 100: 10913-10918.
19. Crowe, N. Y., A. P. Uldrich, K. Kyparissoudis, K. J. L. Hammond, K. Hayakawa, S. Sidobre, R. Keating, M. Kronenberg, M. J. Smyth, and D. I. Godfrey. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol. 171: 4020-4027.
20. Harada, M., K. I. Seino, H. Wakao, S. Sakata, Y. Ishizuka, T. Ito, S. Kojo, T. Nakayama, and M. Taniguchi. 2004. Down-regulation of the invariant Va14 antigen receptor in NKT cells upon activation. Int. Immunol. 16: 241-247.
21. Parekh, V. V., M. T. Wilson, D. Olivares-Villagomez, A. K. Singh, L. Wu, C.-R. Wang, S. Joyce, and L. Van Kaer. 2005. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115: 2572-2583.
22. Ulrich, A. P., N. Y. Crowe, K. Kyparissoudis, D. G. Pellicci, Y. Zhan, A. M. Lew, P. Bouillet, A. Strasser, M. J. Smyth, and D. I. Godfrey. 2005. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bimdependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175: 3092-3101.
23. Ikarashi, Y., A. Iizuka, Y. Koshidaka, Y. Heike, Y. Takaue, M. Yoshida, M. Kronenberg, and H. Wakasugi. 2005. Phenotypical and functional alterations during the expansion phase of invariant Va14 natural killer T (Vα14i NKT) cells in mice primed with α-galactosylceramide. Immunology 116: 30-37.
24. Fujii, S., K. Shimizu, M. Kronenberg, and R. M. Steinman. 2002. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3: 867-874.
25. Parekh, V. V., S. Lalani, and L. Van Kaer. 2006. The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol. 26: 31-48.
26. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704.
27. Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824.
28. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
29. Nishimura, H., T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, A. Mizoguchi, H. Hiai, N. Minato, and T. Honjo. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319-322.
30. Okazaki, T., Y. Tanaka, R. Nishio, T. Mitsuiye, A. Mizoguchi, J. Wang, M. Ishida, H. Hiai, A. Matsumori, N. Minato, and T. Honjo. 2003. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9: 1477-1483.
31. Fife, B. T., I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone. 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203: 2737-2747.
32. Tsushima, F., S. Yao, T. Shin, A. Flies, S. Flies, H. Xu, K. Tamada, D. M. Pardoll, and L. Chen. 2007. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110: 180-185.
33. Saibil, S. D., E. K. Deenick, and P. S. Ohashi. 2007. The sound of silence: modulating anergy in T lymphocytes. Curr. Opin. Immunol. 19: 658-664.
34. Nishimura, H., N. Minato, T. Nakano, and T. Honjo. 1998. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10: 1563-1572.
35. Bezbradica, J. S., A. K. Stanic, and S. Joyce. 2006. Characterization and functional analysis of mouse invariant natural T (iNKT) cells. Curr. Protoc. Immunol. 14.13.1-14.13.27.
36. Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8: 765-772.
37. Yamazaki, T., H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D. M. Pardoll, K. Okumura, M. Azuma, and H. Yagita. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169: 5538-5545.
38. Parekh, V. V., A. K. Singh, M. T. Wilson, D. Olivares-Villagomez, J. S. Bezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, C. R. Wang, S. Joyce, and L. Van Kaer. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173: 3693-3706.
39. Kim, S., S. Lalani, V. V. Parekh, T. L. Vincent, L. Wu, and L. Van Kaer. 2008. Impact of bacteria on the phenotype, functions and therapeutic activities of iNKT cells in mice. J. Clin. Invest. 118: 2301-2315.
40. Halder, R. C., C. Aguilera, I. Maricic, and V. Kumar. 2007. Type II NKT cellmediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Invest. 117: 2302-2312.
41. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
42. Zhong, X., J. R. Tumang, W. Gao, C. Bai, and T. L. Rothstein. 2007. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur. J. Immunol. 37: 2405-2410.
43. Ito, T., T. Ueno, M. R. Clarkson, X. Yuan, M. M. Jurewicz, H. Yagita, M. Azuma, A. H. Sharpe, H. Auchincloss, Jr., M. H. Sayegh, and N. Najafian. 2005. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 174: 6648-6656.
44. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
45. Wilson, M. T., A. K. Singh, and L. Van Kaer. 2002. Immunotherapy with ligands of natural killer T cells. Trends Mol. Med. 8: 225-231.
46. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99: 1259-1266.
47. Chiba, A., C. C. Dascher, G. S. Besra, and M. B. Brenner. 2008. Rapid NKT cell responses are self-terminating during the course of microbial infection. J. Immunol. 181: 2292-2302.
48. Choi, H. J., H. Xu, Y. Geng, A. Colmone, H. Cho, and C. R. Wang. 2008. Bacterial infection alters the kinetics and function of iNKT cell responses. J. Leukocyte Biol. 84: 1462-1471.
49. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
50. Macian, F., S. H. Im, F. J. Garcia-Cozar, and A. Rao. 2004. T-cell anergy. Curr. Opin. Immunol. 16: 209-216.
51. Osman, Y., T. Kawamura, T. Naito, K. Takeda, L. Van Kaer, K. Okumura, and T. Abo. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of a-galactosylceramide. Eur. J. Immunol. 30: 1919-1928.
52. Chang, W. S., J. Y. Kim, Y. J. Kim, Y. S. Kim, J. M. Lee, M. Azuma, H. Yagita, and C. Y. Kang. 2008. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 181: 6707-6710.
53. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
54. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
55. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411-417.
56. Greenwald, R. J., V. A. Boussiotis, R. B. Lorsbach, A. K. Abbas, and A. H. Sharpe. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity 14: 145-155.
57. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
58. Tupin, E., T. Kinjo, and M. Kronenberg. 2007. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5: 405-417.
59. Matsuda, J. L., T. Mallevaey, J. Scott-Browne, and L. Gapin. 2008. CD1d-restricted iNKT cells, the "Swiss-Army knife" of the immune system. Curr. Opin. Immunol. 20: 358-368.